BLAINJECTIONSOLUTION1 Generic Approved
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ENOBY (denosumab-qbde) by Hikma is rank ligand blocking activity [moa]. Approved for rank ligand inhibitor [epc]. First approved in 2025.
Drug data last refreshed 43m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENOBY is a RANK ligand inhibitor monoclonal antibody approved by the FDA on September 26, 2025, as a biosimilar formulation (denosumab-qbde) of the reference biologic denosumab. It blocks RANK ligand signaling to reduce osteoclast activity and bone resorption across multiple indications. This is Hikma's entry into the competitive denosumab market during a period of significant patent erosion for the originator.
Launch
ENOBY enters at launch stage in a mature, competitive market with moderate pricing pressure (30% competitive intensity); early-stage teams will focus on contracting, reimbursement, and managed-care access.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ENOBY offers entry into the biosimilar market at launch stage with early exposure to contracting, payer negotiation, and access strategy—skills valuable in the growing biosimilar sector. However, the crowded competitive landscape and lack of differentiation mean career growth depends on demonstrating rapid market penetration and contracting success within a 2–3 year window before margin compression.
Brand Manager
Worked on ENOBY at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.